Skip to main content
SpringerLink
Log in

Growth Hormone Therapy in Children

  • Chapter
Hormone Replacement Therapy

Part of the book series: Contemporary Endocrinology ((COE,volume 13))

  • 142 Accesses

Abstract

The first documented therapeutic use of growth hormone (GH) occurred in 1958 in an effort to treat a GH-deficient adolescent (1). Further studies confirmed that human GH improved the growth of children with severe GH deficiency (GHD). However, owing to the limited supply of pituitary-derived GH, treatment was limited to only a few thousand patients, and therapy was often sporadic. The use of the pituitary-derived human GH continued until 1985. At that time, a link between the pituitary derived hormone and Jakob-Creutzfeldt disease was reported, resulting in the cessation of the therapeutic use of this medication (2,3) in the US. Fortunately, biosynthetic forms of GH quickly became available. With improved safety and essentially limitless supplies, the therapeutic use of GH has increased dramatically.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 169.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 219.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Raben MS. Treatment of pituitary dwarf with human growth hormone. J Clin Endocrinol Metabol 1958; 18: 901–903.

    Article  CAS  Google Scholar 

  2. Hintz RL. The prismatic case of Creutzfeldt-Jakob disease associated with pituitary growth hormone treatment. J Clin Endocrinol Metabol 1995; 80: 2298–2301.

    Article  CAS  Google Scholar 

  3. Fradkin JE, Schonberger LB, Mills JL, Gunn WJ, Piper JM, Wysowski DK, Thomson R, Durako S, Brown P. Creutzfeldt-Jakob disease in pituitary growth hormone recipients in the United States. J Am Med Assoc 1991; 265: 880–884.

    Article  CAS  Google Scholar 

  4. National Center for Health Statistics:NCHS Growth Curves for Children 0–18 years, United States, Vital and Health Statistics, Series 11, no. 165, Washington, D.C. Health Resources Administration, U.S. Government Printing Office, 1977.

    Google Scholar 

  5. Tanner JM, Davies PSW. Clinical longitudinal standards for height and height velocity for North American children. J Pediatr 1985; 107: 317–329.

    Article  PubMed  CAS  Google Scholar 

  6. Tanner J. Auxology. In: Kappy MS, Blizzard RM, Migeon CJ, eds. The Diagnosis and Treatment of Endocrine Disorders in Childhood and Adolescence, 4th ed. Charles C. Thomas, Springfield, IL, pp. 137–192.

    Google Scholar 

  7. Fitzhardinge PM, Inwood S. Long-term growth in small-for-date children. Acta Paediatr Scandin 1989: 349: 27–33.

    Article  CAS  Google Scholar 

  8. Van Cauter E, Plat L. Physiology of growth hormone secretion during sleep. J Pediatr 1996: 128: S32–37.

    Article  PubMed  Google Scholar 

  9. Radetti G, Bozzola M, Paganini C, Valentin R, Gentili L, Tettoni K, Tato L. Growth hormone bioactivity and levels of growth hormone, growth hormone-binding protein, insulinlike growth factor I, and insulinlike growth factor-binding proteins in premature and full-term newborns during the first month of life. Arch Pediatr Adoles Med 1997: 151: 170–175.

    Article  CAS  Google Scholar 

  10. Rose SR, Municchi G, Barnes KM, Kamp GA, Uriarte MM, Ross JL, Cassorla F, Cutler GB. Spontaneous growth hormone secretion increases during puberty in normal girls and boys. J Clin Endocrinol Metabol 1991; 73: 428–435.

    Article  CAS  Google Scholar 

  11. Costin G, Kaufman FR, Brasel JA. Growth hormone secretory dynamics in subjects with normal stature. J Pediatr 1989; 115: 537–544.

    Article  PubMed  CAS  Google Scholar 

  12. Van Coevorden A, Mockel J, Laurent E, Kerkhofs M, L’ Hermite-Baleriaux M, Decoster C, Neve P, Van Cauter E. Neuroendocrine rhythms and sleep in aging men. Am J Physiol 1991; 260: E651–661.

    PubMed  Google Scholar 

  13. Martin-Hernandez T, Galvez MD, Cuadro AT Herrera-Justiniano E. Growth hormone secretion in normal prepubertal children: importance of relations between endogenous secretion, pusatility and body mass. Clin Endocrinol 1996; 44: 327–344.

    CAS  Google Scholar 

  14. Humbel RE. Insulin-like growth factors I and II. Euro J Biochem 1990; 190: 445–462.

    Article  CAS  Google Scholar 

  15. Hesse, V, Jahreis G, Schambach H, Vogel H, Vilser C, Seewald HJ, Borner A, Deichl A. Insulin-like growth factor I correlations to changes of the hormonal status in puberty and age. Exp Clin Endocrinol 1994; 102, 289–298.

    Article  PubMed  CAS  Google Scholar 

  16. Attie KM, Julius JR, Stoppani C, Rundle AC. National Cooperative Growth Study substudy VI:The clinical utility of growth-hormone-binding protein, insulin-like growth factor I, and insulin-like growth factor-binding protein 3 measurements. J Pediatr 1997; 131: S56–60.

    Article  PubMed  CAS  Google Scholar 

  17. Nunez SB, Municchi G, Barnes KM, Rose SR. Insulin-like growth factor I (IGF-I) and IGF-Binding protein-3 concentrations compared to stimulated and night growth hormone in the evaluation of short children–A clinical research center study. J Clin Endocrinol Metabol 1996; 81: 1927–1931.

    Article  CAS  Google Scholar 

  18. Neely EK, Rosenfeld RG. Use and abuse of human growth hormone. Ann Rev Med 1994; 45: 407–420.

    Article  PubMed  CAS  Google Scholar 

  19. Frasier SD. A review of growth hormone stimulation tests in children. Pediatrics 1974; 53: 929–936.

    PubMed  CAS  Google Scholar 

  20. Ghigo E, Bellone J, Aimaretti G, Bellone S, Loche S, Cappa M, Bartolotta E, Dammacco F, Camanni F. Reliability of provocative tests to assess growth hormone secretory status Study in 472 normally growing children. J Clin Endocrinol Metabol 1996; 81: 3323–3327.

    Article  CAS  Google Scholar 

  21. Rowe DW, Sare Z, Kelley VC. Possible complications of the levodopa-propranolol test. Pediatrics 1977; 60: 132, 133.

    Google Scholar 

  22. Shah A, Stanhope R, Matthew D. Hazards of pharmacological tests of growth hormone secretion in childhood. Brit Med J 1992; 304: 173, 174.

    Google Scholar 

  23. Adan L, Souberbielle JC, Brauner R. Diagnostic markers of permanent idiopathic growth hormone deficiency. J Clin Endocrinol Metabol 1994; 78: 353–358.

    Article  CAS  Google Scholar 

  24. Carel JC, Tresca JP, Letrait M, Chaussain JL, Lebouc Y, Job JC, Coste J. Growth hormone testing for the diagnosis of growth hormone deficiency in childhood:A population register-based study. J Clin Endocrinol Metabol 1997; 82: 2117–2121.

    Article  CAS  Google Scholar 

  25. Tassoni P, Cacciari E, Cau M, et al. Variability of growth hormone response to pharmacological and sleep test performed twice in short children. J Clin Endocrinol Metabol 1990; 71: 230–234.

    Article  CAS  Google Scholar 

  26. Rosenfeld RG, Albertsson-Wikland K, Cassorla F, Frasier SG, Hasegawa Y, Hintz RL, LaFranchi S, Lippe B, Loriaux L, Melmed S, Preece MA, Ranke MB, Reiter EO, Rogol AD, Underwood LE, Werther GA. Diagnostic controversy: the diagnosis of childhood growth hormone deficiency revisited. J Clin Endocrinol Metabol 1995; 80: 1532–1540.

    Article  CAS  Google Scholar 

  27. Marin G, Domene HM, Barnes KM, Blackwell BJ, Cassorla FG, Cutler Jr GB. The effects of estrogen priming and puberty on the growth hormone response to standardized treadmill exercise and arginineinsulin in normal girls and boys. J Clin Endocrinol Metabol 1994; 79: 537–541.

    Article  CAS  Google Scholar 

  28. Florini JR, Prinz, PN, Vitiello MV, Hintz RL. Somatomedin-C levels in healthy young and old men:relationship to peak and 24-hour integrated levels of growth hormone. J Gerontol 1985; 40: 2–7.

    Article  PubMed  CAS  Google Scholar 

  29. Veldhuis JD, Iranmanesh A Physiological regulation of the human growth hormone (GH)-insulin-like growth factor type I (IGF-I) axis:predominant impact of age, obesity, gonadal function, and sleep. Sleep 1996; 19 (10 Suppl): S221 - S224

    PubMed  CAS  Google Scholar 

  30. Celniker AC, Chen AB, Wert RM Jr, et al. Variability in the quantitation of circulating growth hormone using commercial immunoassays. J Clin Endocrinol Metabol 1989; 68: 469–476.

    Article  CAS  Google Scholar 

  31. Granada ML, Sanmarti A, Lucas A, Salinas I, Carrascosa A, Foz M, Audi L. Assay dependent results of immunoassayable spontaneous 24-hour growth hormone secretion in short children. Acta Paediatr Scandin 1990; 370: 63–70.

    Article  CAS  Google Scholar 

  32. Donaldson DL, Hollowell JG, Pan F, Gifford RA, Moore WV. Growth hormone secretory profiles: variation on consecutive nights. J Pediat 1989; 115: 51–56.

    Article  PubMed  CAS  Google Scholar 

  33. Spiliotis BE, August GP, Hung W, et al. Growth hormone neurosecretory dysfunction. A treatable cause of short stature. J Am Med Assoc 1984; 251: 2223–2230.

    Article  CAS  Google Scholar 

  34. Plotnick LP, Lee PA, Migeon CJ, et al. Comparison of physiological and pharmacological tests of growth hormone function in children with short stature. J Clin Endocrinol Metabol 1979; 48: 811–815.

    Article  CAS  Google Scholar 

  35. Bercu BB, Shulman D, Root AW, et al. Growth hormone (GH) provocative testing frequently does not reflect endogenous GH secretion. J Clin Endocrinol Metabol 1986; 63: 709–716.

    Article  CAS  Google Scholar 

  36. Rose SR, Ross JL, Uriarte M, et al. The advantage of measuring stimulated as compared with spontaneous growth hormone levels in the diagnosis of growth hormone deficiency. N Engl J Med 1988; 319: 201–207.

    Article  PubMed  CAS  Google Scholar 

  37. Rosenfeld RG, Wilson DM, Lee PDK, et al. Insulin-like growth factors I and II in the evaluation of growth retardation. J Pediat 1986; 109: 428–433.

    Article  PubMed  CAS  Google Scholar 

  38. Rosenfeld RG. Editorial. Is growth hormone deficiency a viable diagnosis? J Clin Endocrinol Metabol 1997; 82: 349–351.

    Article  CAS  Google Scholar 

  39. Hoffman DM, O’ Sullivan AJ, Baxter RC, Ho KKY. Diagnosis of growth-hormone deficiency in adults. Lancet 1994; 343: 1064–1068.

    Article  PubMed  CAS  Google Scholar 

  40. Baum HBA, Biller BMK, Katznelson L, et al. Assessment of growth hormone (GH) secretion in men with adult-onset GH deficiency compared with that in normal men: a Clinical Research Center Study. J Clin Endocrinol Metabol 1996; 81: 84–92.

    Article  CAS  Google Scholar 

  41. Attanasio AF, Lamberts SWJ, Matranga AMC et al. Adult Growth Hormone (GH)-deficient patients demonstrate heterogeneity between childhood onset and adult onset before and during human GH treatment. J Clin Endocrinol Metabol 1997; 82: 82–88.

    Article  CAS  Google Scholar 

  42. Werther GA. Growth hormone measurements versus auxiology in treatment decisions: the Australian experience. J Pediat 1996; 128: S47–51.

    Article  PubMed  CAS  Google Scholar 

  43. Hintz RL. Current and potential therapeutic uses of growth hormone and insulin-like growth factor I. Endocrinol Metabol Clin N Am 1996; 25: 759–773.

    Article  CAS  Google Scholar 

  44. Chernausek SD, Breen TJ, Frank GR. Linear growth in response to growth hormone treatment in children with short stature associated with intrauterine growth retardation: the National Cooperative Growth Study experience. J Pediat 1996; 128: S22–27.

    Article  PubMed  CAS  Google Scholar 

  45. Wilson DM. Clinical actions of growth hormone. Endocrinol Metabol Clin N Am 1992: 21 (3): 519–537.

    CAS  Google Scholar 

  46. Arky R, ed. Physicians’ Desk Reference, 52nd ed. Medical Economics, Inc., Montvale, NJ, 1998, 990–992.

    Google Scholar 

  47. MacGillivray MH, Baptista J, Johanson A. Outcome of a four-year randomized study of daily versus three times weekly somatotropin treatment in prepubertal naive growth hormone-deficient children. J Clin Endocrinol Metabol 1996; 81: 1806–809.

    Article  CAS  Google Scholar 

  48. de Boer H, Blok GJ, Popp-Snijders C, Stuurman L, Baxter RC, van der Veen E. Monitoring of growth hormone replacement therapy in adults, based on measurement of serum markers. J Clin Endocrinol Metabol 1996; 81: 1371–1377.

    Article  Google Scholar 

  49. Massa G, Vanderschueren-Lodeweyckx M, Bouillon R. Five-year follow-up of growth hormone antibodies in growth hormone deficient children treated with recombinant human growth hormone. Clin Endocrinol 1993; 38: 137–142.

    Article  CAS  Google Scholar 

  50. Kaplan SL, August GP, Blethen SL, Brown DR, Hintz RL, Johansen A, Plotnick LP, Underwood LE, Bell JJ, Blizzard RM, Foley TP, Hopwood NJ, Kirkland RT, Rosenfeld RG, Van Wyk JJ. Clinical studies with recombinant-DNA-derived methionyl human growth hormone in growth hormone deficient children. Lancet 1986; I: 697–700.

    Article  Google Scholar 

  51. Milner RDG, Barnes ND, Buckler JMH, Carson DJ, Hadden DR, Hughes IA, Johnston DI, Parkin JM, Price DA, Rayner PH, Savage DCL, Savage MO, Smith CS, Swift PG. United Kingdom multicentre clinical trial of somatrem. Arch Dis Childhood 1987; 62: 776–779.

    Article  CAS  Google Scholar 

  52. Pirazzoli P, Cacciari E, Mandini M, Cicognani A, Zucchini S, Sganga T, Capelli M. Follow-up antibodies to growth hormone in 210 growth hormone-deficient children treated with different commercial products. Acta Paediatr 1995; 84: 1233–236.

    Article  PubMed  CAS  Google Scholar 

  53. Malozowski S, Tanner LA, Wysowski D, Fleming GA. Growth hormone, insulin-like growth factor I, and benign intracranial hypertension. N Engl J Med 1993; 329: 665, 666.

    Google Scholar 

  54. Blethen SL, Allen DB, Graves D, August G, Moshang T, Rosenfeld R. Safety of recombinant deoxyribonucleic acid-derived growth hormone: The National Cooperative Growth Study experience. J Clin Endocrinol Metab 1996; 81: 1704 1710.

    Google Scholar 

  55. Sponseller PD, Tolo VT. Bone, joint and muscle problems. In: Oski FA, ed. Principles and Practice of Pediatrics. Lippincott, Philadelphia, pp. 943–944.

    Google Scholar 

  56. Styne DM. The testes: disorders of sexual differentiation and puberty. In: Sperling MA, ed. Pediatric Endocrinology. W.B. Saunders, Philadelphia, p. 467.

    Google Scholar 

  57. Allen DB. Safety of human growth hormone therapy: current topics. J Pediatr 1996; 28: S8–13.

    Google Scholar 

  58. Watanabe S, Tsunematsu Y, Fujimoto J, et al. Leukaemia in patients treated with growth hormone (letter). Lancet 1988; 331: 1159–1160.

    Article  Google Scholar 

  59. Allen DB, Rundle AC, Graves DA, Blethen SL. Risk of leukemia in children treated with human growth hormone:Review and reanalysis. J Pediatr 1997; 131: S32–36.

    Article  PubMed  CAS  Google Scholar 

  60. Beshyah SA, Freemantle C, Shah M, Anyaoku V, Merson S, Lynch S, Skinner E, Sharp P, Foale R, Johnston DG. Replacement treatment with biosynthetic human growth hormone in growth hormone-deficient hypopituitary adults. Clin Endocrinol 1995; 42: 73–84.

    Article  CAS  Google Scholar 

  61. Baum HBA, Biller BMK, Finkelstein JS, Cannistraro KB, Oppenheim DS, Schoenfeld DA, Michel TH, Wittink H, Klibanski A. Effects of physiologic growth hormone therapy on bone density and body composition in patients with adult-onset growth hormone deficiency. Ann Intern Med 1996; 125: 883–890.

    PubMed  CAS  Google Scholar 

  62. Lindsay R, Feldkamp M, Harris D, Robertson J, Rallison M. Utah Growth Study:Growth standards and the prevalence of growth hormone deficiency. J Pediatr 1994; 125: 29–35.

    Article  PubMed  CAS  Google Scholar 

  63. Furlanetto RW and the members of the Drug and Therapeutics Committee of the Lawson Wilkins Pediatric Endocrine Society. Guidelines for the use of growth hormone in children with short stature. J Pediatr 1995; 127: 857–867.

    Google Scholar 

  64. Coste J, Letrait M, Carel JC, Tresca JP, Chatelain P, Rochiccioli P, Chaussain JL, Job JC. Long term results of growth hormone treatment in France in children of short stature:population, register based study. Brit Med J 1997; 315: 708–713.

    Article  PubMed  CAS  Google Scholar 

  65. Meling TR, Nylen ES. Growth hormone deficiency in adults: a review. Am J Med Sci 1996; 311: 153–166.

    Article  PubMed  CAS  Google Scholar 

  66. Juul A, Jorgensen JO, Christiansen JS, Muller J, Skakkeboek NE Metabolic effects of GH: a rationale for continued GH treatment of GH-deficient adults after cessation of linear growth. Hormone Res 1995;44 Suppl 3: 64–72

    Google Scholar 

  67. Toogood AN, Shalet SM. The prevalence of severe growth hormone deficiency in adults who received growth replacement in childhood. Clin Endocrinol 1996; 44: 311–316.

    Article  Google Scholar 

  68. Nass R, Huber RM, Klauss V, Muller OA, Schopohl J, Strasburger Cl Effect of growth hormone (hGH) replacement therapy on physical work capacity and cardiac and pulmonary function in patients with hGH deficiency acquired in adulthood. J Clin Endocrinol Metabol 1995; 80 (2): 552–557.

    Article  CAS  Google Scholar 

  69. Allen BD, Brook CGD, Bridges NA, Hindmarsh PC, Guyda, HJ, Frazier D. Therapeutic controversies: growth hormone (GH) treatment of non-GH deficient subjects. J Clin Endocrinol Metabol 1994; 79: 1239–1241.

    Article  CAS  Google Scholar 

  70. Loche S, Cambiaso P, Setzu S, Carta D, Marini R, Borrelli P, Cappa M. Final height after growth hormone therapy in non-growth-hormone-deficient children with short stature. J Pediatr 1994; 125: 196–200.

    Article  PubMed  CAS  Google Scholar 

  71. Kawai m, Momoi T, Yorifuji T, Yamanaka C, Sasaki H, Furusho K. Unfavorable effects of growth hormone therapy on the final height of boys with short stature not caused by growth hormone deficiency. J Pediatr 1997; 130: 205–209.

    Google Scholar 

  72. Wit JM, Boersma B, de Muinck Keizer-Schrama SMPF, Nienhuist HE, Oostdijk W, Otten BJ, Delemarre-Van de Waal HA, Reeser M, Waelkens JJJ, Rikken B, Massa GG. Long-term results of growth hormone therapy in children with short stature, subnormal growth rate and normal growth response to secretagogues. Clin Endocrinol 1995; 42: 365–372.

    Article  CAS  Google Scholar 

  73. Hindmarsh PC, Brook CGD. Final height of short normal children treated with growth hormone. Lancet 1996; 348: 13–16.

    Article  PubMed  CAS  Google Scholar 

  74. Guyda HJ. Use of growth hormone in children with short stature and normal growth hormone secretion. Trends Endocrinol Metabol 1994; 5: 334–340.

    Article  CAS  Google Scholar 

  75. Hintz RL, Attie KM, Johanson AJ, Baptista J, Roche AF and the Genentech Study Group. Near final height in GH-treated short children without classical GH deficiency (abstract). Pediatr Res 1995; 37: 91A.

    Google Scholar 

  76. Zadik A, Chalew S, Zung A, Landau H, Leiberman E, Koren R, Voet H, Hochberg Z, Kowarski AA. Effect of long-term growth hormone therapy on bone age and pubertal maturation in boys with and without classic growth hormone deficiency. J Pediatr 1994; 125: 189–195.

    PubMed  CAS  Google Scholar 

  77. Wit JM, Massarano AA, Kamp GA, Hindmarsh PC, Es AV, Brook CGD, Preece MA, Matthews DR. Growth hormone secretion in patients with Turner’s syndrome as determined by time series analysis. Acta Endocrinol 1992; 127: 7–12.

    PubMed  CAS  Google Scholar 

  78. Ranke MB, Blum WF, Haug F, Rosendahl W, Attanasio A, Enders H, Gupta D, Bierich JR. Growth hormone, somatomedin levels and growth regulation in Turner’s syndrome. Acta Endocrinol 1987; 116: 305–313.

    PubMed  CAS  Google Scholar 

  79. Schmitt K, Haeusler G, Blumel P, Plochl E, Frisch H. Short-and long-term (final height) growth responses to growth hormone (GH) therapy in patients with Turner’ s Syndrome: correlation of growth response to stimulated GH levels, spontaneous GH secretion, and kayotype. Hormone Res 1997; 47: 67–72.

    Article  PubMed  CAS  Google Scholar 

  80. Pasquino AM, Passeri F, Municchi G, Segni M, Pucarelli I, Larizza D, Bossi G, Severi F, Galasso C. Final height in Turner’s Syndrome patients treated with growth hormone. Hormone Res 1996; 46: 269–272.

    Article  PubMed  CAS  Google Scholar 

  81. Attanasio A, James D, Reinhardt R, Rekers-Mombarg L. Final height and long-term outcome after growth hormone therapy in Turner’s Syndrome: results of a German multicentre trial. Hormone Res 1995; 43: 147–149.

    Article  PubMed  CAS  Google Scholar 

  82. Takano K, Ogawa M, Tanaka T, Tachibana K, Fujita K, Hizuka N, Members of the Committee for the Treatment of Turner’ s Syndrome. Clinical trials of GH treatment in patients with Turner’ s Syndrome in Japan: a consideration of final height. Euro J Endocrinol 1997; 137: 138–145.

    Google Scholar 

  83. Rosenfeld RG, and the Genentech National Cooperative Study Group. Growth hormone therapy in Turner’s syndrome: an update on final height. Acta Paediatr Suppl 1992; 383: 3–6.

    Google Scholar 

  84. Wilson DM, Frane JW, Sherman B, Johanson AJ, Hintz RL, Rosenfeld RG, and the Genentech Turner’ s Collaborative Group. Carbohydrate and lipid metabolism in Turner’s syndrome: effect on therapy with growth hormone, oxandrolone, and a combination of both. J Pediatr 1988; 112: 210–217.

    Google Scholar 

  85. Kohaut ED, Fine RN. Testing for growth hormone release is not necessary prior to treatment of children with chronic renal insufficiency with recombinant human growth hormone. Kidney Intl 1996; 49 (S53): S 119–122.

    Google Scholar 

  86. Fine RN, Kohaut E, Brown D, Kuntze J, Attie KM. Long-term treatment of growth retarded children with chronic renal insufficiency, with recombinant human growth hormone. Kidney Intl 1996; 49: 781–785.

    Article  CAS  Google Scholar 

  87. Mehls O, Tonshoff B, Tonshoff C, Haffner D, Blum WF. Therapeutic value of recombinant human growth hormone in children with chronic renal failure. Min Electrolyte Metabol 1992; 18: 320–324.

    CAS  Google Scholar 

  88. Mentser M, Breen TJ, Sullivan D, Fine RN. Growth-hormone treatment of renal transplant recipients: the National Cooperative Growth Study experience: a report of the National Cooperative Growth Study and the North American Pediatric Renal Transplant Cooperative Study. J Pediatr 1997; 131: 520–524.

    Google Scholar 

  89. Wang R, Hirschberg R. Role of growth factors in acute renal failure. Nephrol Dialysis Transplant 1997; 12: 1560–1563.

    Article  CAS  Google Scholar 

Download references

Authors
  1. Catherine K. Lum MD, MPH
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Darrell M. Wilson MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Division of Endocrinology and Medicine, Department of Internal Medicine, University of Utah School of Medicine, Salt Lake City, UT, USA

    A. Wayne Meikle MD

Rights and permissions

Reprints and permissions

Copyright information

© 1999 Springer Science+Business Media New York

About this chapter

Cite this chapter

Lum, C.K., Wilson, D.M. (1999). Growth Hormone Therapy in Children. In: Meikle, A.W. (eds) Hormone Replacement Therapy. Contemporary Endocrinology, vol 13. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-59259-700-0_3

Download citation

  • DOI: https://doi.org/10.1007/978-1-59259-700-0_3

  • Publisher Name: Humana Press, Totowa, NJ

  • Print ISBN: 978-1-61737-092-2

  • Online ISBN: 978-1-59259-700-0

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation